{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:13:56Z","timestamp":1789953236175,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.revmed.2015.09.014","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T23:00:12Z","timestamp":1446246012000},"page":"343-349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunog\u00e9nicit\u00e9 des biom\u00e9dicaments\u00a0: quelles cons\u00e9quences au cours du traitement de la polyarthrite rhumato\u00efde\u00a0?"],"prefix":"10.1016","volume":"37","author":[{"given":"P.","family":"Goupille","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.revmed.2015.09.014_bib0145","first-page":"ii31","article-title":"Immunogenicity of recombinant human proteins: causes and consequences","volume":"251","author":"Schellekens","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.revmed.2015.09.014_bib0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2015.09.014_bib0155","first-page":"40","article-title":"The immunogenicity, safety and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis","volume":"25","author":"Dore","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2015.09.014_bib0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jim.2010.09.005","article-title":"A novel method for the detection of antibodies to adalimumab in the presence of drug reveals \u201chidden\u201d immunogenicity in rheumatoid arthritis patients","volume":"362","author":"van Schouwenburg","year":"2010","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.revmed.2015.09.014_bib0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jim.2015.01.007","article-title":"Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients","volume":"418","author":"Bloem","year":"2015","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.revmed.2015.09.014_bib0170","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2015.09.014_bib0175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.09.014_bib0180","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2015.09.014_bib0185","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2015.09.014_bib0190","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2015.09.014_bib0195","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2009.112847","article-title":"Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study","volume":"69","author":"Bartelds","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2015.09.014_bib0200","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1002\/art.34680","article-title":"Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity","volume":"64","author":"Krieckaert","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2015.09.014_bib0205","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2015.09.014_bib0210","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/art.30463","article-title":"Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2015.09.014_bib0215","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2015.09.014_bib0220","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2015.09.014_bib0225","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/ar3386","article-title":"Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases","volume":"13","author":"Ducourau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2015.09.014_bib0230","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bcp.12313","article-title":"Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis","volume":"78","author":"Ternant","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2015.09.014_bib0235","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2015.09.014_bib0240","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Du Pan","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2015.09.014_bib0245","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2015.09.014_bib0250","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2015.09.014_bib0255","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jbspin.2010.02.021","article-title":"Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients","volume":"77","author":"Finckh","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2015.09.014_bib0260","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2011-200184","article-title":"Patients non-responding to etanercept obtain lower etanercept concentrations compared to responding patients","volume":"71","author":"Jamnitski","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2015.09.014_bib0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2015.09.014_bib0270","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2015.09.014_bib0275","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","author":"Yanai","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.revmed.2015.09.014_bib0140","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866315006712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866315006712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:36:09Z","timestamp":1759336569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866315006712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0248866315006712"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2015.09.014","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunog\u00e9nicit\u00e9 des biom\u00e9dicaments\u00a0: quelles cons\u00e9quences au cours du traitement de la polyarthrite rhumato\u00efde\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2015.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}